Zymeworks To Present Preliminary Results From Phase 1 Study Evaluating ZW191, ADC Targeting Folate Receptor-⍺, At AACR-NCI-EORTC Conference 2025.

Author: Benzinga Newsdesk | October 13, 2025 03:02pm

• Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer.
• Data from the Phase 1 trial of ZW191 provide readthrough to Zymeworks' broader ADC portfolio utilizing its novel bystander active topoisomerase-1 inhibitor payload, ZD06519.

VANCOUVER, British Columbia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the acceptance of a poster presentation discussing preliminary results from a Phase 1 study evaluating ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, being held October 22-26, 2025, in Boston, MA.

Posted In: ZYME